When challenged with factor IX concentrate, inhibitor patients are either low or high responders Low responders are patients who develop a low titer of inhibitor ( 5 Bethesda Units/BU) 50% of inhibitors are low titer and transient "Bypassing agents" are coagulation factor treatment products that do .
Pathology Outlines Factor IX inhibitor
![whatsapp](/images/whatsapp.png)